Skip to main content
SpringerLink
Log in

The Role of Anti-IgE Therapy in Combination with Allergen Specific Immunotherapy for Seasonal Allergic Rhinitis

  • Novel Therapeutic Strategies
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Novel therapies that interfere specifically with immunologic mechanisms underlying allergen-induced pathology are currently in clinical evaluation. Among these is anti-IgE, which directly targets IgE serum antibodies, thus inhibiting the central mechanism of immediate-type hypersensitivity reactions. Application of anti-IgE antibodies effectively reduces IgE serum levels regardless of allergen specificity. Anti-IgE therapy has been successfully tested in patients with allergic rhinitis, asthma, and food allergy, showing significant efficacy in reducing symptom scores and the use of rescue medications. However, such therapy is limited by high costs and the requirements for permanent or every-season treatment. The advantage of specific immunotherapy (SIT) is the potential to alter the course of the disease, which has been demonstrated in patients with allergic rhinitis, insect venom allergy and, to a lesser degree, asthma. The broader application of SIT is restricted by sometimes life-threatening adverse effects. The combination of anti-IgE with SIT was suggested to be superior to each single treatment protocol in children and adolescents with allergic rhinitis. In a randomized, double-blind trial to assess the efficacy and safety of anti-IgE (omalizumab) or placebo in combination with SIT (birch pollen or grass pollen), the combination therapy reduced symptom load, the sum of daily symptom severity score plus rescue medication use, over the birch and grass pollen seasons by nearly 50% over SIT alone. These data show that the combination of anti-IgE plus SIT may be beneficial for the treatment of allergic diseases, offering improved efficacy, limited adverse effects, and potential immune-modifying effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Johansson SG, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56 (9): 813–24

    Article  PubMed  CAS  Google Scholar 

  2. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998; 12 (2): 315-35

  3. Beasley R, Crane J, Lai CK, et al. Prevalence and etiology of asthma. J Allergy Clin Immunol 2000; 105 (2 Pt 2): S466–72

    Article  PubMed  CAS  Google Scholar 

  4. Mitchell EA. Asthma epidemiology: clues and puzzles. Pediatr Pulmonol 1999; 18 Suppl.: 31–3

    Article  CAS  Google Scholar 

  5. British guideline on the management of asthma. Thorax 2003; 58 Suppl. 1: i1–94

    Google Scholar 

  6. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics: 2002. J Allergy Clin Immunol 2002; 110 (5 Suppl.): S141–219

    Google Scholar 

  7. Fireman P. Therapeutic approaches to allergic rhinitis: treating the child. J Allergy Clin Immunol 2000 Jun; 105 (6 Pt 2): S616–21

    Article  PubMed  CAS  Google Scholar 

  8. Stock P, Akbari O, DeKruyff RH, et al. Respiratory tolerance is inhibited by the administration of corticosteroids. J Immunol 2005; 175 (11): 7380–7

    PubMed  CAS  Google Scholar 

  9. Fick Jr RB, Fox JA, Jardieu PM. Immunotherapy approach to allergic disease. Immunopharmacology 2000; 48 (3): 307–10

    Article  PubMed  CAS  Google Scholar 

  10. Bryan SA, Leckie MJ, Hansel TT, et al. Novel therapy for asthma. Expert Opin Investig Drugs 2000; 9 (1): 25–42

    Article  PubMed  CAS  Google Scholar 

  11. Barnes PJ. Anti-IgE therapy in asthma: rationale and therapeutic potential. Int Arch Allergy Immunol 2000; 123 (3): 196–204

    Article  PubMed  CAS  Google Scholar 

  12. Busse WW, Rosenwasser LJ. Mechanisms of asthma. J Allergy Clin Immunol 2003; 111 (3 Suppl.): S799–804

    Article  PubMed  CAS  Google Scholar 

  13. Hamelmann E, Gelfand EW. IL-5-induced airway eosinophilia: the key to asthma? Immunol Rev 2001; 179: 182–91

    Article  PubMed  CAS  Google Scholar 

  14. Presta L, Shields R, O’ Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994; 269 (42): 26368–73

    PubMed  CAS  Google Scholar 

  15. Saban R, Haak-Frendscho M, Zine M, et al. Human FcERI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. J Allergy Clin Immunol 1994; 94 (5): 836–43

    Article  PubMed  CAS  Google Scholar 

  16. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151 (5): 2623–32

    PubMed  CAS  Google Scholar 

  17. Hamelmann E, Rolinck-Werninghaus C, Wahn U. From IgE to anti-IgE: where do we stand? Allergy 2002; 57 (11): 983–94

    Article  PubMed  CAS  Google Scholar 

  18. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001 Dec 19; 286 (23): 2956–67

    Article  PubMed  CAS  Google Scholar 

  19. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997 Jun; 155 (6): 1828–34

    PubMed  CAS  Google Scholar 

  20. MacGlashan Jr DW, Bochner BS, Adelman DC, et al. Down-regulation of Fc (epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158 (3): 1438–45

    PubMed  CAS  Google Scholar 

  21. Fox JA, Hotaling TE, Struble C, et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996; 279 (2): 1000–8

    PubMed  CAS  Google Scholar 

  22. FickJr RB. Anti-IgE as novel therapy for the treatment of asthma. Curr Opin Pulm Med 1999; 5 (1): 76–80

    Article  PubMed  Google Scholar 

  23. Jardieu PM, Fick JrRB. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol 1999; 118 (2-4): 112–5

    Article  PubMed  CAS  Google Scholar 

  24. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100 (1): 110–21

    Article  PubMed  CAS  Google Scholar 

  25. Fahy JV, Cockcroft DW, Boulet LP, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999; 160 (3): 1023–7

    PubMed  CAS  Google Scholar 

  26. Mailing HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53 (5): 461–72

    Article  Google Scholar 

  27. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994; 93 (2): 413–23

    Article  PubMed  CAS  Google Scholar 

  28. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99 (1 Pt 1): 22–7

    PubMed  CAS  Google Scholar 

  29. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an antiIgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106 (2): 253–9

    Article  PubMed  CAS  Google Scholar 

  30. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286 (23): 2956–67

    Article  PubMed  CAS  Google Scholar 

  31. Plewako H, Arvidsson M, Petruson K, et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002; 110 (1): 68–71

    Article  PubMed  CAS  Google Scholar 

  32. Frew AJ. Immunotherapy of allergic disease. J Allergy Clin Immunol 2003; 111 (2 Suppl.): S712–9

    Article  PubMed  Google Scholar 

  33. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97 (6): 1356–65

    Article  PubMed  CAS  Google Scholar 

  34. Ebner C, Siemann U, Bohle B, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27 (9): 1007–15

    Article  PubMed  CAS  Google Scholar 

  35. Bellinghausen I, Knop J, Saloga J. The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol 2001; 126 (2): 97–101

    Article  PubMed  CAS  Google Scholar 

  36. Asthma and Immunology. Allergen immunotherapy: a practice parameter. American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 2003; 90 (1 Suppl. 1): 1–40

    Google Scholar 

  37. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, et al. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001 Jul; 87 (1 Suppl. 1): 47–55

    Article  PubMed  CAS  Google Scholar 

  38. Mailing HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf 2000 Oct; 23 (4): 323–32

    Article  Google Scholar 

  39. Greenberg MA, Kaufman CR, Gonzalez GE, et al. Late and immediate systemicallergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol 1986 Jun; 77 (6): 865–70

    Article  PubMed  CAS  Google Scholar 

  40. Lockey RF, Benedict LM, Turkeltaub PC, et al. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987 Apr; 79 (4): 660–77

    Article  PubMed  CAS  Google Scholar 

  41. Bousquet J, Lockey R, Mailing HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases: a WHO position paper. J Allergy Clin Immunol 1998; 102 (4 Pt 1): 558–62

    Article  PubMed  CAS  Google Scholar 

  42. Varney VA, Gaga M, Frew AJ, et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302: 265–9

    Article  PubMed  CAS  Google Scholar 

  43. Varney VA, Edwards J, Tabbah K, et al. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997; 27 (8): 860–7

    Article  PubMed  CAS  Google Scholar 

  44. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grasspollen immunotherapy. N Engl J Med 1999; 341 (7): 468–75

    Article  PubMed  CAS  Google Scholar 

  45. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002; 57 (4): 306–12

    Article  PubMed  CAS  Google Scholar 

  46. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PATstudy). J Allergy Clin Immunol 2002; 109: 251–6

    Article  PubMed  Google Scholar 

  47. Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year follow-up study. Clin Exp Allergy 2001; 31 (9): 1392–7

    Article  PubMed  CAS  Google Scholar 

  48. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with antiIgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109 (2): 274–80

    Article  PubMed  CAS  Google Scholar 

  49. Kopp MV, Brauburger J, Riedinger F, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 110 (5): 728–35

    Article  PubMed  CAS  Google Scholar 

  50. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006 Jan; 117 (1): 134–40

    Article  PubMed  CAS  Google Scholar 

  51. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001; 164 (8 Pt 2): S1–5

    PubMed  CAS  Google Scholar 

  52. Nayak A, Casale T, Miller SD, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2003 Sep; 24 (5): 323–9

    PubMed  CAS  Google Scholar 

  53. Hamelmann E, Takeda K, Schwarze J, et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes. Am J Respir Cell Mol Biol 1999; 21 (4): 480–9

    PubMed  CAS  Google Scholar 

  54. Oettgen HC, Martin TR, Wynshaw-Boris A, et al. Active anaphylaxis in IgEdeficient mice. Nature 1994; 370 (6488): 367–70

    Article  PubMed  CAS  Google Scholar 

  55. Takeda K, Hamelmann E, Joetham A, et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med 1997; 186 (3): 449–54

    Article  PubMed  CAS  Google Scholar 

  56. Hamelmann E, Cieslewicz G, Schwarze J, et al. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med 1999; 160 (3): 934–41

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Pediatric Pneumology and Immunology, Charité University Medicine, Augustenburger Platz 1, Berlin, D-13353, Germany

    Philippe Stock, Claudia Rolinck-Werninghaus, Ulrich Wahn &  Eckard Hamelmann

Authors
  1. Philippe Stock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Rolinck-Werninghaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulrich Wahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eckard Hamelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eckard Hamelmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stock, P., Rolinck-Werninghaus, C., Wahn, U. et al. The Role of Anti-IgE Therapy in Combination with Allergen Specific Immunotherapy for Seasonal Allergic Rhinitis. BioDrugs 21, 403–410 (2007). https://doi.org/10.2165/00063030-200721060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200721060-00007

Keywords

Search

Navigation